Tuesday, December 1, 2020

Pfizer faces inquiry over foreign bribery in China


Pfizer Inc. said it received an inquiry from the U.S. Securities and Exchange Commission’s foreign-bribery unit regarding the drugmaker’s operations in China.

The inquiry was disclosed in Pfizer’s third-quarter financial statement, which was filed with regulators Thursday. It follows other informal requests for information by the SEC and the U.S. Justice Department related to Pfizer’s business in China and Russia.

- Advertisement -

New York-based Pfizer received the SEC inquiry about its China operations in August, and the Justice Department inquiry in June, the company said. The inquiries were sent from the agencies’ Foreign Corrupt Practices Act units.

The FCPA prohibits companies from paying bribes to foreign officials to gain a business advantage. The SEC and the Justice Department play a role in enforcing the law.

- Advertisement -

The SEC and Justice Department’s FCPA units last year requested information about Pfizer’s operations in Russia, according to the filing.

Pfizer said it was producing records in response to the requests. A company spokeswoman declined to comment further on the disclosure.

Companies in the health-care sector have long been the subject of scrutiny by antibribery authorities, in part due to their frequent interaction with foreign officials and regulators. In many countries, hospitals and clinics are state-run, and doctors and other health-care professionals can be considered government officials.

Boston-based Alexion Pharmaceuticals Inc. in July agreed to pay more than $21 million to settle claims it bribed officials to increase prescription drug sales in Turkey and Russia. In June, Swiss drugmaker Novartis AG and a former subsidiary reached a combined $347 million settlement to resolve allegations that the companies ran schemes to bribe public hospitals in Greece, Vietnam and South Korea.

Pfizer has had past run-ins with U.S. authorities over allegations of bribery among its operations abroad. The company in 2012 agreed to pay $60.2 million to settle investigations by the SEC and the Justice Department into alleged violations of the FCPA in several countries in Europe and Asia, including China and Russia.

Pfizer is among the companies developing a vaccine for the novel coronavirus. In October, the company said a global late-stage trial evaluating its experimental vaccine was almost fully enrolled with participants.

The U.S. government has placed an initial order with Pfizer for 100 million doses of any completed vaccine, with the option to purchase 500 million additional doses.


Subscribe For More

Get our daily notification on the latest financial crimes news around the World

- Affiliate Products -


Latest News

This Week

OxyContin maker Purdue Pharma pleads guilty to fraud and kickback in U.S. opioid crisis probe

Purdue Pharma LP pleaded guilty to criminal charges over the handling of its addictive prescription painkiller OxyContin, capping a deal with federal prosecutors to...

Indonesian Fisheries Minister Edhy Prabowo arrested over corruption in lobster seed export case

Indonesia's Fisheries Minister Edhy Prabowo faces up to life in jail after being arrested by the country's Anti-Corruption Commission over lobster larvae export permits. The...

Former Cincinnati council member Tamaya Dennard gets 18 months prison in corruption case

Former Cincinnati City Council Member Tamaya Dennard was sentenced on Tuesday for her part in what federal authorities say is a “culture of corruption”...

Venezuelan court jails six former Citgo executives for corruption

A Venezuelan court sentenced six former executives of U.S. refiner Citgo to prison after finding them guilty of corruption charges on Thursday. The officials were...

Adblock Detected!

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by whitelisting our website.

Enable Notifications    OK No thanks